newsfilter
← Latest News
PR Newswire·

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in...